Research programme: targeted antibody therapeutics - Juno Therapeutics
Latest Information Update: 05 Aug 2016
At a glance
- Originator AbVitro
- Developer Juno Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research HIV infections; Multiple sclerosis; Pancreatic cancer
Most Recent Events
- 17 Apr 2015 Early research in HIV infections, Multiple sclerosis and Pancreatic cancer in USA (unspecified route)